Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

Inclusion Criteria:

• Male or Female participants 5 to < 18 years of age at the time of randomization.

• Participant must have a confirmed diagnosis of juvenile psoriatic arthritis (JPsA)according to the International League of Associations for Rheumatology (ILAR)Edmonton Revision (Petty, 2001) classification criteria of at least 6 monthsduration:

• Arthritis and psoriasis, OR

• Arthritis with at least 2 of the following:

• Dactylitis

• Nail pitting or onycholysis

• Psoriasis in a first-degree relative

• Active disease: at least 3 active joints.

• Inadequate response (at least 2 months) or intolerance to ≥ 1 disease-modifyinganti-rheumatic drugs (DMARD), (which may include methotrexate [MTX] or biologicagents).

Exclusion Criteria:

• Exclusions per ILAR Edmonton Revision (Edmonton, 2001) criteria for JPsA include:

• Arthritis in an HLA-B27-positive male with arthritis onset after 6 years of age

• Ankylosing spondylitis, sacroiliitis with inflammatory bowel disease, Reiter'ssyndrome, acute anterior uveitis, or a history of one of these disorders in afirst-degree relative

• History of IgM rheumatoid factor on at least 2 occasions at least 3 monthsapart

• Presence of systemic juvenile idiopathic arthritis (JIA).

• Rheumatic autoimmune disease other than psoriatic arthritis (PsA), including, butnot limited to: systemic lupus erythematosus, mixed connective tissue disease,scleroderma, polymyositis, or fibromyalgia.

• Prior history of or current inflammatory joint disease other than PsA (eg, gout,reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).